98%
921
2 minutes
20
Accurate prostate segmentation in transrectal ultrasound (TRUS) is a challenging problem due to the low contrast of TRUS images and the presence of imaging artifacts such as speckle and shadow regions. To address this issue, we propose a semi-automatic model termed Hybrid Segmentation Model (H-SegMod) for prostate Region of Interest (ROI) segmentation in TRUS images. H-SegMod contains two cascaded stages. The first stage is to obtain the vertices sequences based on an improved principal curve-based model, where a few radiologist-selected seed points are used as prior. The second stage is to find a map function for describing the smooth prostate contour based on an improved machine learning model. Experimental results show that our proposed model achieved superior segmentation results compared with several other state-of-the-art models, achieving an average Dice Similarity Coefficient (DSC), Jaccard Similarity Coefficient (Ω), and Accuracy (ACC) of 96.5%, 95.2%, and 96.3%, respectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209717 | PMC |
http://dx.doi.org/10.3389/fonc.2022.878104 | DOI Listing |
Radiother Oncol
September 2025
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Purpose: To predict metastasis-free survival (MFS) for patients with prostate adenocarcinoma (PCa) treated with androgen deprivation therapy (ADT) and external radiotherapy using clinical factors and radiomics extracted from primary tumor and node volumes in pre-treatment PSMA PET/CT scans.
Materials/methods: Our cohort includes 134 PCa patients (nodal involvement in 28 patients). Gross tumor volumes of primary tumor (GTVp) and nodes (GTVn) on CT and PET scans were segmented.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFInt Urol Nephrol
September 2025
Portsmouth Hospitals, University NHS Trust, Portsmouth, UK.
Prostate cancer (PCa) remains one of the most prevalent cancers among men, with over 1.4 million new cases and 375,304 deaths reported globally in 2020. Current diagnostic approaches, such as prostate-specific antigen (PSA) testing and trans-rectal ultrasound (TRUS)-guided biopsies, are often Limited by low specificity and accuracy.
View Article and Find Full Text PDFRev Esp Med Nucl Imagen Mol (Engl Ed)
September 2025
Department of Biostatistics, Gaziantep University, Gaziantep, Turkey.
Objective: This study aimed to assess the predictive value of metastatic distribution patterns on Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.
Materials And Methods: A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression.
J Med Chem
September 2025
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
We designed and synthesized a novel type of PSMA radioligand incorporating (2, 3) β-branched aromatic α-amino acids within the linker segment of its structure. PET/CT imaging and biodistribution analysis revealed that β-branched aromatic α-amino acids modified PSMA radioligands could maintain or even improve tumor targeting while exhibiting a more rapid renal clearance rate than [Ga]Ga-. With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [Ga]Ga-, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks.
View Article and Find Full Text PDF